TFA
ALNY icon

Transamerica Financial Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Transamerica Financial Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.5M Sell
8,288
-1,015
-11% -$306K 0.21% 111
2026
Q1 		$3.08M Buy
9,303
+697
+8% +$237K 0.26% 97
2025
Q4 		$3.42M Buy
8,606
+8,529
+11,077% +$3.77M 0.29% 97
2025
Q3 		$35.1K Buy
+77
New +$31.4K ﹤0.01% 522

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Transamerica Financial Advisors's ALNY Position: Q2 2026 in Review

Transamerica Financial Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 11% in Q2 2026, selling an estimated $306K and leaving 8,288 shares worth $2.5M. The position accounts for 0.21% of the portfolio, ranked #111.

Transamerica Financial Advisors first reported a position in ALNY in Q3 2025 and has held it in 4 quarters since. The position peaked at $3.42M in Q4 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Transamerica Financial Advisors held 8,288 shares of Alnylam Pharmaceuticals worth $2.5M as of Q2 2026.
  • Transamerica Financial Advisors sold 1,015 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $306K.
  • Alnylam Pharmaceuticals made up 0.21% of Transamerica Financial Advisors's portfolio in Q2 2026, its #111 holding.
  • Transamerica Financial Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Transamerica Financial Advisors's Alnylam Pharmaceuticals position peaked at $3.42M in Q4 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Transamerica Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.